Co-Diagnostics, Inc. Strengthens Zika Customer Base in Caribbean Basin
August 24 2017 - 7:30AM
Business Wire
Sales expected upon successful performance
evaluation and validation
Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or
the “Company”), a molecular diagnostics company with a unique,
proprietary platform for the development of diagnostic tests,
announced today that they have strengthened relationships with key
regional customers throughout the Caribbean basin to purchase the
Company’s Zika virus diagnostic.
The potential customer base includes laboratories, regional
health ministries, and hospitals interested in offering a
state-of-the-art molecular diagnostic for the Zika virus to their
customers, citizens, and patients. To date, Company representatives
and future product distributors have conducted on-site suitability
assessments at dozens of locations in countries across the region,
with the understanding that these locations would be among the
first to have access to the Zika virus test upon completion of
successful performance evaluation and validation studies. The
Company is also an approved reseller of diagnostic equipment, to
enable upgraded laboratory facilities for those locations who have
not previously been able to offer molecular diagnostics.
Dwight Egan, Co-Diagnostics CEO, remarked, “Molecular
diagnostics are the internationally recognized gold standard in
disease detection, and Co-Diagnostics’ assays are built on our own
platform without expensive royalty payments built in to the cost.
We are uniquely positioned to assist the many overlooked and
underserved populations in this region interested in a
competitively priced, high quality diagnostic tool to assist in the
detection of the Zika virus.”
About Co-Diagnostics, Inc.:Co-Diagnostics, Inc., a Utah
corporation, is a molecular diagnostics company that has developed
and intends to manufacture and sell reagents used for diagnostic
tests that function via the detection and/or analysis of nucleic
acid molecules (DNA or RNA), and to sell diagnostic equipment from
other manufacturers as self-contained lab systems.
Forward-Looking Statements:This press release contains
forward-looking statements. Forward-looking statements can be
identified by words such as "believes," "expects," "estimates,"
"intends," "may," "plans," "will" and similar expressions, or the
negative of these words. Such forward-looking statements are based
on facts and conditions as they exist at the time such statements
are made and predictions as to future facts and conditions. Readers
of this press release are cautioned not to place undue reliance on
any forward-looking statements. The Company does not undertake any
obligation to update any forward-looking statement relating to
matters discussed in this press release, except as may be required
by applicable securities laws.
Disclaimer:This news release does not constitute an offer
to sell or a solicitation of an offer to buy the securities
described herein, nor shall there be any sale of these securities
in any state or jurisdiction in which such an offer, solicitation
or sale would be unlawful prior to registration or qualification
under the securities laws of any such state or jurisdiction.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170824005416/en/
Co-Diagnostics Investor RelationsSeth Egan,
801-438-1036s.egan@codiagnostics.com
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Co Diagnostics (NASDAQ:CODX)
Historical Stock Chart
From Apr 2023 to Apr 2024